Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus LCS-742
- Development stage
- Unknown
- Lead developer
- Morinaga Milk Industry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus LCS-742 is a probiotic strain of the gram-positive lactic acid bacterium *Lacticaseibacillus rhamnosus* (formerly *Lactobacillus rhamnosus*), developed by Morinaga Milk Industry. It is primarily utilized in pediatric nutrition and clinical research, often in combination with *Bifidobacterium longum subsp. infantis M-63* and prebiotic fibers. The strain is designed to colonize the infant gastrointestinal tract, where it modulates the gut microbiota and supports the development of the immune system. Clinical studies have demonstrated its efficacy in reducing crying time in infants with colic, improving gastrointestinal tolerance, and potentially preventing the development of atopic dermatitis in high-risk infants. It is characterized by its stability in powdered formulations and its ability to survive gastric transit to exert beneficial effects in the intestines.
- Other names
- Lacticaseibacillus rhamnosus LCS-742L. rhamnosus LCS-742
02
Targets
EGFR (Epidermal growth factor receptor)HTR4 (5-Hydroxytryptamine receptor 4)FPR1 (Formyl peptide receptor 1)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Lactobacillus rhamnosus LCS-742.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus LCS-742.